870 related articles for article (PubMed ID: 24004658)
1. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
2. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
3. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.
Sermet-Gaudelus I
Eur Respir Rev; 2013 Mar; 22(127):66-71. PubMed ID: 23457167
[TBL] [Abstract][Full Text] [Related]
4. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
5. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
6. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
7. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
10. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
11. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
12. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
13. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
14. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
[TBL] [Abstract][Full Text] [Related]
15. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
17. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
[TBL] [Abstract][Full Text] [Related]
18. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
O'Reilly R; Elphick HE
Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
[TBL] [Abstract][Full Text] [Related]
19. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
